Pyxis Oncology Q2 loss widens on increased administrative costs
Pyxis Oncology Q2 loss widens on increased administrative costs
Overview
US cancer therapeutics developer's Q2 net loss widened yr/yr as operating expenses rose
Company completed $50 mln private placement, extending cash runway into Q2 2027
R&D expenses declined, while general and administrative costs increased on higher severance and stock compensation
Outlook
Company expects to report updated MICVO Phase 1 monotherapy data in Fall 2026
Company expects to report updated MICVO Phase 1/2 combination data in Q4 2026
Company says cash runway extended into Q2 2027 after recent financing
Result Drivers
PRIVATE PLACEMENT - Co completed $50 mln private placement, extending cash runway into Q2 2027
R&D EXPENSES - Research and development expenses declined, mainly due to lower manufacturing costs
ADMINISTRATIVE COSTS - General and administrative expenses increased due to higher severance and stock-based compensation
Company press release: ID:nGNX8XJMk8
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Loss Per Share |
| $0.40 |
|
Q2 Net Loss |
| $25.35 mln |
|
Q2 Income from Operations |
| -$25.99 mln |
|
Q2 Operating Expenses |
| $25.99 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Pyxis Oncology Inc is $7.00, about 120.1% above its August 12 closing price of $3.18
Reuters Recommended Reads
Aug 11 - Oncology firm Immunome's Q2 net loss widens as R&D costs rise
Aug 11 - Cardiff Oncology Q2 operating expenses fall on lower R&D costs
Aug 12 - Aprea Therapeutics Q2 net loss widens on higher R&D costs
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)